Proactive - Interviews for investors

Sarytogan Graphite Ltd (ASX:SGY) CEO Sean Gregory sits down with Jonathan Jackson to discuss a major technical milestone with Sarytogan’s graphite now used in lithium-ion batteries. The first lithium-ion batteries have been made using the company’s uncoated spherical purified graphite (USPG), with early tests indicating they outperform many existing synthetic graphite anodes used in electric vehicles. Not only did the company post excellent capacity results, the batteries demonstrated significant repeatability and consistency across all tests, with no noticeable performance degradation after multiple charge and discharge cycles. Sarytogan now plans to continue long-term testing on USPG cells and start a second round of tests on coated spherical purified graphite (CSPG), which involves a surface coating process expected to further enhance battery performance. Finally, Gregory speaks about the upcoming PFS, due in Q3, which will highlight its low cost base and high revenue outcomes.

#ProactiveInvestors #SarytoganGraphite #ASX #BatteryMetals #Graphite

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Vivos Therapeutics CEO Kirk Huntsman joined Steve Darling from Proactive to highlight certain significant favorable market developments creating new opportunities to widen its funnel of potential users of Vivos’ oral appliance therapies. This after the U.S. FDA granted, for the first time ever, a clearance to the Vivos CARE appliances to treat moderate and severe OSA in adults, 18 years of age and older along with positive airway pressure and/or myofunctional therapy, as needed.

Huntsman highlighted several other factors contributing to the positive market conditions for Vivos. The recent discontinuation of many devices by Philips Respironics is expected to disrupt the supply chain, potentially affecting patient care. Additionally, the recalls of continuous positive airway pressure (CPAP) devices have left millions of OSA sufferers searching for alternative treatments.

United Healthcare's recognition of oral appliance therapy as a prerequisite for surgical treatment in adult patients with moderate to severe OSA is another important development. These factors are collectively creating a significant opportunity for Vivos to expand its user base and offer effective treatment options to those in need.

#proactiveinvestors #vivostherapeuticsinc #nasdaq #vvos #biopharma

#sleepapnea, #FDAapproval, #oralappliances, #healthtech, #medicaldevices, #CPAPrecall, #UnitedHealthcare, #hypoglossalnerve, #Inspireimplants, #sleepdisorders, #patientcare, #healthcareindustry, #marketdisruption, #CEOinterview, #medicalinnovation, #treatmentoptions, #physicianeducation, #awarenesscampaign, #industryupdates, #healthnews, #digitalhealth, #sleeptherapy, #innovativetreatments#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Filament Health CEO Ben Lightburn joined Steve Darling from Proactive to share some groundbreaking news. The U.S. Food and Drug Administration (FDA) has given its approval for the Investigational New Drug application for PEX010, Filament Health's botanical psilocybin drug candidate designed for the treatment of Substance Use Disorders. This significant development now paves the way for Filament Health to commence research activities in the United States, focusing on the potential use of their botanical psilocybin drug candidate in addressing substance use disorders, including those involving opioids.

Lightburn went on to explain that the IND-opening protocol had previously been submitted to Health Canada and had received the department's no-objection status, underlining the company's commitment to adhering to rigorous regulatory standards on both sides of the border.

Moreover, Lightburn highlighted the extensive scope of research and collaboration surrounding PEX010. Currently, a network of 24 research institutions and licensing partners across Canada, the USA, Europe, and Israel is actively studying PEX010 for various conditions. These include but are not limited to alcohol use disorder, depression, and coma, showcasing the versatile potential of this botanical psilocybin drug candidate in addressing a wide range of medical conditions.

The acceptance of the IND application by the FDA marks a pivotal moment in Filament Health's journey, offering a pathway for innovative and potentially transformative treatments for substance use disorders. It also underscores the company's global reach and collaborative efforts in advancing the field of psychedelic medicine. This milestone is a testament to the commitment of Filament Health to research and develop solutions that hold promise for individuals struggling with these challenging conditions.

#proactiveinvestors #filamenthealthcorp #otcqb #flhlf #cboe #fh @pex010 #resetpharma #depression

#FDAapproval, #substanceusedisorder, #opioidaddiction, #psilocybin, #botanicalmedicine, #clinicaltrial, #healthcarenews, #mentalhealthawareness, #drugdevelopment, #researchupdate, #FDAguidelines, #medicalinnovation, #opioidcrisis, #treatmentoptions, #mentalwellness, #pharmacology, #drugdiscovery, #healthtech, #publichealth, #medicalresearch, #addictionrecovery, #drugpolicy, #psychedelictherapy

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

In a recent conversation with Steve Darling from Proactive, Kevin Carter, the Founder and Chief Investment Officer of EMQQ Global and the INQQ Fund, delved into the dynamic landscape of emerging markets, focusing specifically on the contrasting trajectories of India and China. Carter underscored India's promising growth prospects, drawing parallels and distinctions with China's remarkable economic ascent over the past two decades.

Highlighting India's strengths, Carter pointed to its vast and youthful population, burgeoning economy, and thriving tech sector as key drivers of growth. He elaborated on India's innovative digital infrastructure, which plays a pivotal role in fostering financial inclusion and driving technological advancements across various sectors.

Despite India's relatively high market valuation, Carter emphasized that its growth potential, particularly fueled by its digital initiatives, is often underestimated by many investors. This insightful discussion sheds light on India's evolving role as a significant player in the global economy and underscores the compelling investment opportunities it offers.

For further expert analysis on emerging markets and strategic investment insights, viewers are encouraged to stay tuned to updates from EMQQ Global.

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Trust Stamp President Andrew Gowasack joined Steve Darling from Proactive to unveil a significant development in the company's journey. Trust Stamp has officially entered into a Teaming Agreement with ManTech, marking a pivotal step towards the integration of Trust Stamp's cutting-edge AI-Powered, Privacy-First identity authentication technologies into ManTech's extensive portfolio, particularly enhancing ManTech programs like Zero Trust.

Gowasack elaborated during the interview that this strategic alliance between Trust Stamp and ManTech had its roots in the Georgia Institute of Technology's Advanced Technology Development Center (ATDC), a partner of ManTech. Trust Stamp's notable graduation from ATDC as a Signature Portfolio company highlights the transformative potential of their technology. It's a recognition of their ability to facilitate fully-trusted connections across companies, coaches, capital, and customers.

ManTech, renowned for its track record of successful government engagements and its capacity to deliver cutting-edge analytics, is poised to synergize effectively with Trust Stamp's technology. Together, they aim to offer a premier trust and identity solution tailored to the specific needs of government customers.

This Teaming Agreement symbolizes a fusion of innovative capabilities and domain expertise, a union that holds the promise of revolutionizing identity authentication and trust-building in the government sector. Trust Stamp and ManTech are set to empower organizations with robust tools to navigate the complex landscape of modern data security and privacy, aligning with the principles of Zero Trust. This collaboration is poised to make a profound impact on the world of technology and government services.

#proactiveinvestors #truststamp #nasdaq #idai #globalsecure #datasecurity #privacyprotection

#ManTech, #GovernmentTechnology, #IdentitySolutions, #BiometricSecurity, #DataPrivacy, #Cybersecurity, #FederalGovernment, #Innovation, #TechAlliance, #ATDC, #GeorgiaTech, #FraudPrevention, #IdentityVerification, #PrivacyFirst, #GovernmentContracts, #TrustworthyTechnology, #DigitalSecurity, #DataProtection, #GovernmentFraud, #Biometrics, #ITSecurity, #GovernmentContracts, #TechnologyPartnership#pertnership#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

FPX Nickel CEO Martin Turenne joined Steve Darling from Proactive to unveil a significant addition to the company's leadership team. FPX Nickel proudly announced the appointment of Kim Baird to its Board of Directors, a move that underscores the company's commitment to diversity, inclusion, and strategic expertise.

Baird brings with her a wealth of experience and a distinguished track record as a leader and strategic advisor, particularly in her work with Indigenous communities, governments, businesses, and other organizations. Notably, she previously served as the elected Chief of the Tsawwassen First Nation, where she played a pivotal role in negotiating and implementing British Columbia's first modern urban treaty. This landmark agreement empowered the Tsawwassen People with ownership and governance rights over their land and resources, showcasing Baird's proficiency in Indigenous policy, governance, and economic development.

Recognized as a highly-regarded advocate for Indigenous peoples, Baird's expertise extends to major infrastructure projects, with a keen understanding of the opportunities they present for economic reconciliation and Indigenous participation. Currently serving as the Chancellor of Kwantlen Polytechnic University and as the interim Chief Administrative Officer for the Tsawwassen First Nation, Baird brings a wealth of knowledge and leadership acumen to FPX Nickel.

Her impressive resume also includes previous board positions at BC Hydro and the Greater Vancouver Board of Trade. Currently, she serves as a director on several boards, including the Canada Infrastructure Bank, further underscoring her commitment to shaping impactful policies and strategies across various sectors.

Baird's appointment to the Board of Directors represents a significant milestone for FPX Nickel, as the company continues to position itself as a leader in the mining industry. With Baird's invaluable expertise and leadership, FPX Nickel is poised to navigate complex challenges, drive sustainable growth, and create lasting value for its stakeholders.

#proactiveinvestors #fpxnickelcorp #tsxv #fpx #otcqb #fpocf #batterymetals #nickel

#KimBaird, #BoardOfDirectors, #IndigenousLeadership, #ResourceDevelopment, #MiningIndustry, #Collaboration, #EconomicDevelopment, #IndigenousPolicy, #CommunityEngagement, #BaptisteProject, #TailingsDesign, #BritishColumbia, #FirstNations, #CorporateGovernance, #EnvironmentalImpact, #SustainableDevelopment, #Leadership, #CorporateResponsibility, #MiningOperations, #NaturalResources, #MiningTechnology, #MiningCommunity, #InvestmentOpportunity#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Optica Rare Earths and Criticak Metals ETF Chairman Derek Bone joined Steve Darling from Proactive to delve into the intricacies of this innovative investment opportunity. Bone shed light on the genesis of the ETF, which sprang from the collective expertise of a team boasting backgrounds in mining, finance, and corporate advisory roles, particularly in capital raisings for rare earth companies in Australia.

Drawing inspiration from their success in the gold ETF space and leveraging their extensive network and knowledge, the team made the strategic decision to launch an ETF focused exclusively on rare earths and critical minerals. This expanded thesis encompasses a diverse array of 50 minerals and metals crucial for various industries worldwide.

Bone elaborated on the ETF's primary objective, which is to meticulously track the entire value chain of these critical materials, from the extraction phase to the manufacturing of finished goods. This holistic approach mirrors the escalating significance of clean technology, defense, medical, and communication sectors globally. Moreover, against the backdrop of governments increasingly prioritizing the security of their supply chains for these essential materials, the ETF zeroes in on long-term investment opportunities rather than short-term trading gains.

Despite facing challenges in marketing and distribution, given its relative small size and new entrant status compared to competitors, the ETF is determined to make a significant impact. Bone outlined the ETF's strategy, which revolves around addressing industry pain points and offering innovative solutions. Central to this approach is the emphasis on capital preservation and volatility reduction by strategically investing in key companies within the sector.

In essence, Optica Rare Earths and Critical Metals ETF embodies a forward-thinking approach to investment, poised to capitalize on the burgeoning demand for rare earths and critical minerals while navigating the complexities of the global market landscape. With a steadfast commitment to industry excellence and value creation, the ETF aims to carve out a distinct niche and deliver enduring returns for its investors.

#procctiveinvestors #opticarareearthsandcriticakmetalsETF

#CriticalMetals, #ETF, #Investment, #CleanEnergy, #Defense, #Technology, #Mining, #Finance, #SupplyChain, #GlobalTrends, #GreenEconomy, #ElectricVehicles, #RenewableEnergy, #SolarPower, #WindEnergy, #Recycling, #Manufacturing, #SupplyAndDemand, #Investing, #FinanceNews, #IndustryInsights, #MarketAnalysis, #StockMarket, #YouTubeSEO

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Creo Medical Group CEO Craig Gulliford tells Proactive's Stephen Gunnion that 2023 was a pivotal year for the company.

Amid challenging market conditions, Creo successfully secured crucial funding, setting a foundation for enhanced operational focus rather than fundraising efforts. Key milestones included the launch of the Speedboat UltraSlim, a significant advancement in minimising medical device size, which led to the company's largest quarter in orders and technology uptake. This innovation, alongside the early market release of selected products, received positive feedback and significant regulatory clearances in the US and Europe, propelling Creo towards a robust setup for 2024.

Furthermore, Creo announced progress with its SpydrBlade and MicroBlate programs, showcasing advancements in surgical technology and partnerships with leading robotic surgery firms.

Financially, Creo reported a 13% revenue increase to £30.8 million and a 10% reduction in operating costs, reflecting strategic shifts towards more cost-effective and revenue-generating operations.

These developments signal Creo's transition into a fully commercial business, with a clear path to cash flow breakeven by 2025.

‌

#CreoMedicalGroup #MedicalTechnology #SpeedboatUltra #MedicalInnovation #SurgicalDevices #HealthcareTechnology #MedicalDevices #FinancialUpdate #Commercialization #MedicalDeviceRegulation #RoboticSurgery #PancreaticCancer #LiverCancer #HealthcareInvestment #MedicalResearch #SurgicalInnovation #HealthTech #MedicalIndustry #CEOInterview #BusinessGrowth #HealthcareSolutions #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Redx Pharma PLC CEO Lisa Anson joins Proactive's Stephen Gunnion with details of a landmark partnership with Jazz Pharmaceuticals, marking its largest deal to date.

Anson explained the agreement involves the sale of Redx's KRAS programme, a key preclinical discovery initiative targeting genetic mutations driving various cancers. The $10 million upfront deal could potentially be followed by a further $870 million in milestone payments, signifying a major step forward for Redx in cancer research.

The KRAS programme focuses on combating hard-to-treat cancers, such as colorectal, lung, and pancreatic cancers, by targeting specific genetic mutations. The partnership aligns with RedX's strategy to balance in-house program development with collaborations that accelerate patient access to new treatments.

Anson emphasized the significance of partnerships in advancing their clinical-stage biotech research and development efforts. The deal not only provides immediate financing but also ensures Redx maintains a vested interest in the program's success through potential milestones and mid-single digit royalties on future sales.

Looking ahead, RedX anticipates a busy 2024 with several key milestones, including advancing its fibrosis and oncology programs, further demonstrating its commitment to addressing unmet medical needs.

‌

#RedXPharma #JazzPharmaceuticals #CancerResearch #KRASProgramme #BiotechPartnerships #ClinicalResearch #OncologyInnovation #CancerTherapy #BiotechIndustry #PharmaceuticalNews #DrugDevelopment #CancerGenetics #BiotechCEO #LisaAnson #MedicalBreakthroughs #PharmaCollaborations #InnovativeMedicine #CancerTreatment #PreclinicalResearch #Biotechnology #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

ETC Group CEO Tim Bevan discusses the significant impact of the US Securities and Exchange (SEC)'s approval of Bitcoin ETFs, enhancing market access and legitimizing cryptocurrencies. This approval led to notable market shifts, including outflows from existing crypto products like the Grayscale Bitcoin Trust and inflows into new ETFs from major financial players such as Fidelity and iShares.

Despite initial price weakness following the ETF launch, Bevan attributes this to a natural retracement after Bitcoin's substantial pre-launch appreciation. He anticipates a demand surge, supported by North America's vast financial advisory network, potentially driving over $30 billion into Bitcoin, significantly increasing global Bitcoin product AUM.

Bevan also highlighted Europe's likely follow-up on the US's path towards crypto normalization, driven by the sector's increasing legitimacy.

With bullish outlooks on crypto into 2024 and 2025, backed by aggressive price forecasts, Bevan pointed to the Bitcoin halving event as a key factor for future price appreciation, alongside a favorable macroeconomic backdrop and rising geopolitical risks.

Furthermore, he noted Ethereum's potential for significant price performance and the possibility of Ethereum ETFs following Bitcoin's regulatory success, marking a pivotal moment for broader cryptocurrency acceptance and investment.

‌

#CryptoNews #BitcoinETF #ETCGroup #Cryptocurrency #TimBevan #Bitcoin #Ethereum #SECApproval #CryptoMarket #InvestmentTrends #DigitalAssets #CryptoAdoption #BitcoinHalving #EthereumETF #MarketAccess #FinancialMarkets #CryptoInvesting #BlockchainTechnology #CryptocurrencyAnalysis #FutureOfCrypto #CryptoBullRun #InflationHedge #GeopoliticalRisk #CryptoOutlook #FinancialInnovation #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews